| Recruiting | Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma NCT07388563 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Exp NCT07055477 | National Cancer Institute (NCI) | Phase 1 |
| Withdrawn | Tazemetostat Plus CHOP in 1L T-cell Lymphoma NCT06692452 | Eric Jacobsen, MD | Phase 2 |
| Recruiting | Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Other NCT06561048 | Corvus Pharmaceuticals, Inc. | Phase 3 |
| Recruiting | Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma NCT04234048 | SciTech Development, Inc. | Phase 1 |
| Unknown | Clinical Study of Mitoxantrone Liposome and Azacitidine in the Treatment of R/R AITL NCT06224842 | Huijing Wu | Phase 1 / Phase 2 |
| Active Not Recruiting | Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T- NCT05377827 | Washington University School of Medicine | Phase 1 |
| Recruiting | A Registry for People With T-cell Lymphoma NCT05978141 | Memorial Sloan Kettering Cancer Center | — |
| Unknown | A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types NCT05907447 | Ruijin Hospital | — |
| Unknown | Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lympho NCT05821192 | Ou Bai, MD/PHD | N/A |
| Completed | Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies NCT05290155 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Phase 1 |
| Unknown | An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD3 NCT05208853 | Zhejiang University | EARLY_Phase 1 |
| Unknown | Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma NCT05179213 | Peking Union Medical College Hospital | Phase 2 |
| Suspended | Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma NCT04803201 | Alliance for Clinical Trials in Oncology | Phase 2 |
| Unknown | Sintilimab in Combination With Chidamide in Refractory and Relapsed AITL NCT04831710 | Sun Yat-sen University | Phase 2 |
| Suspended | Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies NCT04828174 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Phase 1 |
| Unknown | CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Labe NCT04480788 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Phase 1 |
| Unknown | Rituximab Combined With Chidamide and Lenalidomide for r/r AITL NCT04319601 | Zhejiang Cancer Hospital | N/A |
| Unknown | Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies NCT04008394 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 1 |
| Unknown | Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell Lympho NCT03853044 | Ruijin Hospital | Phase 2 |
| Terminated | Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymph NCT03590574 | Autolus Limited | Phase 1 / Phase 2 |
| Completed | Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms NCT03493451 | BeiGene | Phase 2 |
| Active Not Recruiting | Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lym NCT03113500 | City of Hope Medical Center | Phase 2 |
| Unknown | Chidamide With PET Regimen for Angioimmunoblastic T Cell Lymphoma (PET: Prednisone, Etoposide and Thalidomide) NCT03273452 | Qingdao University | Phase 2 |
| Completed | Risk Stratification of Nodal PTCL NCT03040206 | Chonbuk National University Hospital | — |
| Completed | A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymp NCT02588651 | Deepa Jagadeesh | Phase 2 |
| Unknown | CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma NCT02742727 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Phase 1 / Phase 2 |
| Completed | Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma NCT02652715 | Mayo Clinic | N/A |
| Unknown | CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL NCT02533700 | Shandong Provincial Hospital | Phase 2 |
| Unknown | Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma NCT02232516 | Northwestern University | Phase 2 |
| Withdrawn | Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgki NCT01769911 | Fred Hutchinson Cancer Center | N/A |
| Completed | Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or An NCT02273739 | Celgene | Phase 1 / Phase 2 |
| Completed | CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lym NCT02168140 | Wake Forest University Health Sciences | Phase 1 |
| Completed | Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Ce NCT01959477 | Case Comprehensive Cancer Center | EARLY_Phase 1 |
| Withdrawn | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Maligna NCT01652014 | University of Medicine and Dentistry of New Jersey | Phase 2 |
| Completed | MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma NCT01748721 | Morphotek | Phase 1 |
| Completed | Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT01839916 | University of Chicago | Phase 2 |
| Active Not Recruiting | Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency NCT01787409 | Mayo Clinic | N/A |
| Terminated | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas NCT01805037 | Northwestern University | Phase 1 / Phase 2 |
| Terminated | Ipilimumab and Local Radiation for Selected Solid Tumors NCT01769222 | Stanford University | Phase 1 |
| Unknown | CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymph NCT01746992 | Ruijin Hospital | Phase 4 |
| Terminated | Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic L NCT01419795 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-C NCT01567709 | National Cancer Institute (NCI) | Phase 1 |
| Unknown | CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study NCT01719835 | Royal Marsden NHS Foundation Trust | Phase 2 |
| Completed | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem NCT01529827 | Roswell Park Cancer Institute | Phase 2 |
| Completed | Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma NCT01466881 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgki NCT01408043 | Case Comprehensive Cancer Center | N/A |
| Completed | Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Trans NCT01427881 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma NCT01336933 | University of Nebraska | Phase 2 |
| Completed | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma NCT01326702 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma NCT01336920 | University of Nebraska | Phase 1 |
| Completed | Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignanci NCT01658319 | Case Comprehensive Cancer Center | Phase 1 |
| Completed | Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma NCT01261247 | Mayo Clinic | Phase 2 |
| Completed | Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma NCT01075321 | Mayo Clinic | Phase 1 / Phase 2 |
| Completed | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies NCT01273766 | Wake Forest University Health Sciences | Phase 2 |
| Active Not Recruiting | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic NCT01199562 | City of Hope Medical Center | — |
| Completed | Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma NCT01258998 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers NCT01254578 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilizati NCT01110135 | University of Washington | Phase 2 |
| Completed | RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas NCT01198665 | Samsung Medical Center | Phase 1 / Phase 2 |
| Completed | RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors NCT01158274 | National Cancer Institute (NCI) | Phase 1 |
| Completed | AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lympho NCT01129193 | Amir Mortazavi | Phase 1 |
| Terminated | Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin L NCT01116154 | City of Hope Medical Center | Phase 1 |
| Completed | Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma NCT01129180 | Pierluigi Porcu | Phase 1 |
| Completed | Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Canc NCT01053494 | Wake Forest University Health Sciences | N/A |
| Completed | Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma NCT00901147 | Singapore General Hospital | Phase 2 |
| Completed | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy NCT00890747 | National Cancer Institute (NCI) | Phase 1 |
| Completed | FAU in Treating Patients With Advanced Solid Tumors or Lymphoma NCT00769288 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hod NCT00918333 | Mayo Clinic | Phase 1 / Phase 2 |
| Terminated | Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating NCT00933985 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With NCT00856388 | Roswell Park Cancer Institute | N/A |
| Completed | Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surg NCT00608361 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Study of MLN8237 in Participants With Advanced Hematological Malignancies NCT00697346 | Millennium Pharmaceuticals, Inc. | Phase 1 |
| Terminated | Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas NCT00704691 | University of Alabama at Birmingham | EARLY_Phase 1 |
| Completed | Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma NCT00644189 | Massachusetts General Hospital | Phase 1 / Phase 2 |
| Completed | Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory NCT00601718 | University of Washington | Phase 1 / Phase 2 |
| Completed | Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction NCT00499811 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, NCT00458731 | National Cancer Institute (NCI) | Phase 1 |
| Completed | 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma NCT00293345 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid NCT00354185 | National Cancer Institute (NCI) | Phase 1 |
| Completed | PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas NCT00348985 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma NCT00112723 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma NCT00131937 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hemat NCT00103272 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofe NCT00118352 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or NCT00101205 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas NCT00096005 | National Cancer Institute (NCI) | Phase 1 |
| Completed | MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas NCT00098891 | National Cancer Institute (NCI) | Phase 1 |
| Completed | 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas NCT00089271 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone To NCT00089011 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma NCT00077155 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Mali NCT00078858 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Trea NCT00072514 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer NCT00049504 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation NCT00040846 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction NCT00025415 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Imm NCT00014235 | Fred Hutchinson Cancer Center | N/A |
| Completed | Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma NCT00006473 | National Cancer Institute (NCI) | Phase 2 |
| Completed | 506U78 in Treating Patients With Lymphoma NCT00005080 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporin NCT00006251 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Terminated | 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma NCT00005950 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenola NCT00112593 | Fred Hutchinson Cancer Center | N/A |
| Completed | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymph NCT00004241 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymph NCT01678443 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma NCT00003970 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte I NCT00003196 | Fred Hutchinson Cancer Center | N/A |
| Completed | High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patient NCT01177371 | Case Comprehensive Cancer Center | Phase 2 |